Hi,
moomoo ID:NaN
Log Out
ENGLISH
  • ENGLISH
  • 中文繁体
  • 中文简体
donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
KOD Kodiak Sciences
7.740
+0.140+1.84%
Post Mkt Price
8.150
+0.410+5.30%
YOY
Do not show
Hide blank lines
(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31(Q4)2021/12/31
Assets
Current assets
Cash, cash equivalents and short term investments
-32.13% 597.88M -27.69% 671.73M -24.51% 731.51M -24.51% 731.51M
-Cash and cash equivalents
-80.4% 172.69M -27.02% 671.73M -22.54% 731.51M -- --
-Short-term investments
-- 425.18M -- -- -- -- -- --
Prepaid assets
87.55% 6.49M 259.2% 10.46M 8.91% 3.3M -- --
Total current assets
-31.66% 604.37M -26.8% 682.19M -24.4% 734.81M -- --
Non current assets
Net PPE
47.55% 117.65M 43.4% 113.81M 37.14% 108.07M -- --
-Gross PPE
47.55% 117.65M 43.4% 113.81M 37.09% 111.01M -- --
-Accumulated depreciation
-- -- -- -- -35.44% -2.94M -- --
Other non current assets
78.6% 59.89M 152.82% 54.3M 270.96% 61.34M -- --
Total non current assets
56.74% 177.54M 66.71% 168.1M 77.69% 169.41M -- --
Total assets
-21.62% 781.91M -17.67% 850.29M -15.28% 904.22M -15.28% 904.22M
Liabilities
Current liabilities
Payables
653.51% 20.63M 42.48% 13.07M 43.78% 12.43M -- --
-accounts payable
653.51% 20.63M 42.48% 13.07M 43.78% 12.43M -- --
Current accrued expenses
16.54% 43.16M 142.06% 58.28M 136.83% 48.32M -- --
Current debt and capital lease obligation
384.29% 6.04M 175.76% 4.98M 65.67% 3.93M -- --
-Current capital lease obligation
384.29% 6.04M 175.76% 4.98M 65.67% 3.93M -- --
Current liabilities
70.24% 69.83M 117.74% 76.33M 105.85% 64.68M -- --
Non current liabilities
Long term debt and capital lease obligation
5.17% 80.99M 0.74% 76.42M 1.38% 76.06M -- --
-Long term capital lease obligation
5.17% 80.99M 0.74% 76.42M 1.38% 76.06M -- --
Due to related parties non current
-- -- -- -- 0.05% 99.94M -- --
Other non current liabilities
42701.71% 100.16M -18.78% 199K -17.58% 211K -- --
Total non current liabilities
2.25% 181.14M 0.32% 176.57M 0.6% 176.22M -- --
Total liabilities
15.03% 250.97M 19.83% 252.9M 16.6% 240.9M 16.6% 240.9M
Shareholders'equity
Share capital
0% 5K 0% 5K 0% 5K -- --
-common stock
0% 5K 0% 5K 0% 5K -- --
-Preferred stock
-- 0 -- 0 -- 0 -- --
Retained earnings
-87.3% -744.55M -91.39% -653.93M -91.68% -558.22M -91.68% -558.22M
Paid-in capital
8.53% 1.28B 7.56% 1.25B 6.04% 1.22B -- --
Gains losses not affecting retained earnings
-- -1.87M -- -- -- -- -- --
Total stockholders'equity
-31.88% 530.93M -27.3% 597.38M -22.94% 663.32M -91.68% -558.22M
Total equity
-31.88% 530.93M -27.3% 597.38M -22.94% 663.32M -22.94% 663.32M
Currency Unit
USDUSDUSDUSD
Accounting Standards
US-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions
----Unqualified Opinion--

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the development of novel therapies for the treatment of retinal diseases. Its product pipeline includes KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and uveitis, KSI-201 for resistant wet AMD, and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.
CEO: Dr. Victor Perlroth, M.D.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...